ENLV
SellFallen FavouriteEnlivex Ltd. · Healthcare · Israel · $71M cap
$0.1627 -6.2% · close 26 Oct · scored 27 Oct
StockRank up 8.5 since 24 Oct: Momentum up 14.
Fallen Favourite: A good business, still expensive, and the price is falling.
As of 27 Oct 2026, MoatMap's StockRank for Enlivex Ltd. (ENLV) is 23/100, ranked against 24,000+ stocks in 35 markets (Quality 55, Value 25, Momentum 27, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT ENLIVEX LTD.
Read
Enlivex Ltd. is a clinical-stage biotechnology company focused on developing Allocetra™, a novel cell-based immunotherapy designed to rebalance the immune system in patients suffering from life-threatening inflammatory and autoimmune conditions. The company's competitive edge lies in its unique approach to modulating the immune system, aiming to prevent and reverse cytokine storms and organ dysfunction. It operates as a specialized biotech firm, with its lead candidate showing promise in severe indications such as sepsis and COVID-19.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — |
| EPS | -12.15 | -1.85 | -1.72 | -1.03 | — | — | — |
| Shares | — | 16.8M | 16.8M | 16.8M | 15.8M | -6.0% | — |
| Debt | — | 4.8M | 1.0M | 0.5M | 0.6M | -49.1% | 17.5M |
| Equity | — | 56.8M | 30.1M | 23.6M | 1.9B | 224.1% | — |
| Op CF | — | -24.0M | -23.5M | -13.0M | -10.4M | — | -15.5M |
| Inv CF | — | 62.5M | -26.0M | 9.1M | -1.3M | — | — |
| Fin CF | — | 0.1M | 0.4M | 6.5M | 10.4M | — | — |
Not enough steady price history for a read yet.
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENLV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENLV | Enlivex Ltd.(you) | $71M | 23 | Sell |
| PYPD | PolyPid Ltd. | $107M | 20 | Strong Sell |
| SLGL | Sol-Gel Technologies Ltd. | $227M | 24 | Sell |
| MDWD | MediWound Ltd. | $155M | 7 | Strong Sell |
| ENTX | Entera Bio Ltd. | $508M | 20 | Sell |
| DRTS | Alpha Tau Medical Ltd. | $1.2B | 25 | Sell |
| CGEN | Compugen Ltd. | $184M | 90 | Strong Buy |
| INCR | InterCure Ltd. | $68M | 33 | Sell |
| BVC.L | BATM Advanced Communications Ltd. | $52M | 33 | Sell |
| NNOX | Nano-X Imaging Ltd. | $55M | 7 | Strong Sell |
Peer medians: ROE -13.8% · P/E 16.0x · Gross margin 52.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.